ArticleJournal of virology1998
trans-encapsidation of a poliovirus replicon by different picornavirus capsid proteins.
Article in Journal of virology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- Development of enterovirus transencapsidation assays as tools to understand viral entry.The Journal of general virology · 2025Article
- An efficientJournal of virology · 2024Article
- Seneca Valley virus replicons are packaged inMolecular therapy oncolytics · 2023Article
- Pseudotyped Viruses for Enterovirus.Advances in experimental medicine and biology · 2023Article
- Trans-Encapsidation of Foot-and-Mouth Disease Virus Genomes Facilitates Escape from Neutralizing Antibodies.Viruses · 2022Article
- Article
- A surrogate assay for measuring Coxsackievirus A6 neutralizing antibodies.Human vaccines & immunotherapeutics · 2018Article
- Limits of variation, specific infectivity, and genome packaging of massively recoded poliovirus genomes.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- A rapid and quantitative assay for measuring neutralizing antibodies of Coxsackievirus B3.Journal of virological methods · 2016Article
- Efficient replication of recombinant Enterovirus B types, carrying different P1 genes in the coxsackievirus B5 replicative backbone.Virus genes · 2015Article
- The encephalomyocarditis virus.Virulence · 2012Review
- Establishment of infectious HCV virion-producing cells with newly designed full-genome replicon RNA.Archives of virology · 2011Article
- Direct interaction between two viral proteins, the nonstructural protein 2C and the capsid protein VP3, is required for enterovirus morphogenesis.PLoS pathogens · 2010Article
- MicroRNA antagonism of the picornaviral life cycle: alternative mechanisms of interference.PLoS pathogens · 2010Article
- 5'-Terminal deletions occur in coxsackievirus B3 during replication in murine hearts and cardiac myocyte cultures and correlate with encapsidation of negative-strand viral RNA.Journal of virology · 2005Article
- Density-dependent selection in vesicular stomatitis virus.Journal of virology · 2004Article
- Coxsackievirus expression of the murine secretory protein interleukin-4 induces increased synthesis of immunoglobulin G1 in mice.Journal of virology · 2000Article
- Formation of the poliovirus replication complex requires coupled viral translation, vesicle production, and viral RNA synthesis.Journal of virology · 2000Article
- Identification of a cis-acting replication element within the poliovirus coding region.Journal of virology · 2000Article
- Requirements for RNA replication of a poliovirus replicon by coxsackievirus B3 RNA polymerase.Journal of virology · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
A trans-encapsidation assay was established to study the specificity of picornavirus RNA encapsidation. A poliovirus replicon with the luciferase gene replacing the capsid protein-coding region was coexpressed in transfected HeLa cells with capsid proteins from homologous or heterologous virus. Successful trans-encapsidation resulted in assembly and production of virions whose replication, upon subsequent infection of HeLa cells, was accompanied by expression of luciferase activity. The amount of luciferase activity was proportional to the amount of trans-encapsidated virus produced from the cotransfection. When poliovirus capsid proteins were supplied in trans, >2 x 10(6) infectious particles/ml were produced. When coxsackievirus B3, human rhinovirus 14, mengovirus, or hepatitis A virus (HAV) capsid proteins were supplied in trans, all but HAV showed some encapsidation of the replicon. The overall encapsidation efficiency of the replicon RNA by heterologous capsid proteins was significantly lower than when poliovirus capsid was used. trans-encapsidated particles could be completely neutralized with specific antisera against each of the donor virus capsids. The results indicate that encapsidation is regulated by specific viral nucleic acid and protein sequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.